Daley breast center opens its doors

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 5
Volume 19
Issue 5

Opening of the Maggie Daley Center for Women’s Cancer Care at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.


From left, Mayor Richard Daley, his wife Maggie Daley (seated), Ann Lurie, and Dr. Steven Rosen at the opening of the Maggie Daley Center for Women's Cancer Care at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

CHICAGO-From left, Mayor Richard Daley, his wife Maggie Daley (seated), Ann Lurie, and Dr. Steven Rosen at the opening of the Maggie Daley Center for Women's Cancer Care at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. The new center will offer women with breast cancer a centralized location for access to clinical trials and novel therapies, psychosocial services, rehabilitation, and integrative oncology services. The center is a partnership between Northwestern Medical Faculty Foundation, the university's Feinberg School of Medicine, Northwestern Memorial, and the Rehabilitation Institute of Chicago.

Recent Videos
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content